Pay in 4 interest-free payments of $7.03 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
Nausea may return briefly after the dose increase
The summary a careful reader should take away: the oncological concern is theoretical and pathway-based
Services Pharmacy Consulting Pharmacy is no longer a side conversation in your benefits strategy
Stahl, 2024)
Safety Profile (Phase 2) The most common adverse events were gastrointestinal and consistent with the incretin drug class: - Nausea - Diarrhea - Vomiting - Constipation - Decreased appetite These GI events were dose-related, mostly mild to moderate, and partially mitigated by starting at a lower initial dose (2 mg vs
US$ 27.28
US$ 28.08
US$ 22.19
US$ 24.87
US$ 26.67
US$ 23.07
US$ 27.51
US$ 22.32
